QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements - Seite 2
Additionally, in anticipation of World TB Day, QIAGEN is hosting a global CPD-accredited event on March 21, 2024, with top TB experts discussing the vital theme of “TB infection screening and preventive therapy for achieving End TB strategy goals”. The program will explore the global TB landscape, advances in testing and prevention, and screening of migrants. A panel discussion will address TB epidemiology, cost-effectiveness, and challenges faced by high-risk groups like migrants and children.
Tuberculosis is a contagious bacterial infection spread primarily by coughing of patients with the active pulmonary form of the disease. The WHO estimated that there were more than 10 million new cases of active TB worldwide and 1.3 million deaths in 2022. One in four people worldwide are believed to have latent TB infections, with 5-10% of them expected at some point to develop active TB. Screening for latent TB infection is therefore essential in the effort to end TB.
QIAGEN’s QuantiFERON-TB Gold Plus assay accurately detects TB infection by identifying interferon-gamma released by T-cells in response to TB-specific antigens. This one-visit test outperforms the century‑old, two-visit TB skin test (TST), particularly for patients from high-TB-burden countries who have received BCG vaccination. The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus to combat the global TB epidemic.
For more information and to register for this event, please visit https://www.qiagen.com/us/applications/tb-management/events/world-tb-d ...
About QIAGEN
Lesen Sie auch
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2023, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.